Previous 10 | Next 10 |
Actively Enrolling Two Phase III Clinical Studies in NSCLC for Ivonescimab: HARMONi and HARMONi-3 Updated Phase II Data Announced for Ivonescimab Highlighting 24-Month OS Rate of 64.8% in 1L Squamous NSCLC Patients and mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC Patients ...
Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...
2024-02-19 00:55:47 ET Major earnings expected before the bell on Monday include: Walmart ( WMT ) The Home Depot ( HD ) Medtronic plc ( MDT ) Transocean Ltd. ( RIG ) Digital Bridge Group ( DBRG ) Read the full article on Seeking Alpha ...
Financial Results & Operational Progress Call on February 20, 2024 Conference Call to be Held at 9:00am ET Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth q...
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at Oppenheimer’s 34 th Annual Healthcare Life Sciences Conference, which will be held virtually. Summit will pres...
2024-01-30 07:16:26 ET Summary Summit's financial position is stable with adequate funds to support operations until H2 2024, despite a significant drop in cash reserves. Ivonescimab, SMMT's dual-acting compound targeting PD-1 and VEGF, shows promise in the field of oncology, part...
2024-01-22 12:04:50 ET Summary Acurx shares opened ~25% lower on Jan 17th, after releasing positive data suggesting its C. diff antibiotic outperformed standard treatment in restoring the gut microbiome. The decline in share price since then may be due to misaligned investor expec...
Phase II 24-Month OS Rate of 64.8% in 1L Squamous NSCLC Patients Phase II mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC Patients Catalyst Events Expected in Q2 2024 for Two Randomized Phase III Trials Evaluating Ivonescimab in China Conducted by Akeso, including Head-to-He...
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 09, 2024, at 1:30 PM PT. Robert W. Duggan, Cha...
2023-11-29 08:23:49 ET Losers: Seelos Therapeutics ( SEEL ) -43% on pricing of $5.55 million stock offering . Leslies ( LESL ) -20% after Q4 earnings release . Farfetch Ltd ( FTCH ) -16% . ESGL Holdings Ltd ( ESGL ) -15% . Petco ...
News, Short Squeeze, Breakout and More Instantly...
Summit Therapeutics Inc. Company Name:
SMMT Stock Symbol:
NASDAQ Market:
Conference Call to be Held at 9:00am ET Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company ...
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. “We are excited to add Dr. Ronaghi to complement our exce...
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Stifel 2024 Targeted Oncology Forum, which will be held virtually April 16-17, 2024. Dr. Maky Zanganeh, Chief Executi...